Deepak Yadav: Practice-Changing Stroke Trial Alert
Deepak Yadav, Consultant and Assistant Professor of Neurology at Amrita Hospital, shared on LinkedIn about a recent article by Yao Lu et al, published in The Lancet:
”Practice-Changing Stroke Trial Alert | The Lancet (2026)
For decades, neuroprotection in acute ischaemic stroke has been the graveyard of failed trials.
Hundreds of agents showed promise in animals… and disappeared in humans.
Until now.
The EMPHASIS trial, a large multicentre, double-blind RCT published in The Lancet, reports that oral minocycline started within 72 hours of acute ischaemic stroke improves 90-day functional outcomes — safely.
What did EMPHASIS show?
- 1,724 patients, NIHSS 4–25
- Minocycline vs placebo (added to standard care)
- mRS 0–1 at 90 days:
52.6% vs 47.4%
Adjusted RR 1.11 (p = 0.006)
- Ordinal mRS shift also significant
- No increase in symptomatic ICH or serious adverse events
This is not a surrogate marker. This is functional recovery.
Why is this IMPORTANT?
Because this trial succeeds where others failed:
- NA-1 (ESCAPE-NA1) – benefit lost after adjustment
- Magnesium (FAST-MAG) – biologically elegant, clinically neutral
- Citicoline (ICTUS) – large trial, no benefit
- NXY-059 (SAINT I and II) – early hope, ultimate disappointment
EMPHASIS is different:
Large sample
Pragmatic design
Clinically meaningful endpoint
Cheap, widely available drug
Oral, easy to implement — even in resource-limited settings
Why might minocycline work?
Because stroke injury is not just vascular — it’s inflammatory.
Minocycline targets:
- Microglial activation
- Matrix metalloproteinases
- BBB disruption
- Secondary neuroinflammation
In short: it addresses the biology of delayed injury, not just reperfusion.
Should we change practice today? Not blindly.
But this trial re-opens the neuroprotection conversation with real data.
Questions that now matter:
Benefit in minor vs severe strokes?
Interaction with thrombolysis / thrombectomy?
Optimal dose and duration?
External validation outside China?
Bottom line:
After years of negative trials, EMPHASIS gives neuroprotection its strongest clinical signal yet.
This is one of those papers we’ll be citing for years.
Do you think minocycline should enter routine post-stroke protocols — or do we wait for replication?
Let’s discuss.”
Title: Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial
Authors: Yao Lu, Ling Guan, Jialing Wu, Qianqian Yang, Meiyang Zhang, Dongyang Zhou, Hongqin Yang, Yuesong Pan, Luyan Wang, Baoshan Qiu, Chenhui Liu, Yicong Wang, Yingying Yang, Xuejiao Zhou, Hui Qu, Xiaoling Liao, Liping Liu, Xingquan Zhao, Philip M Bath, S Claiborne Johnston, Pierre Amarenco, Guillaume Turc, Fu-Dong Shi, Yongjun Wang, Yilong Wang on behalf of the EMPHASIS Investigators
Read the Full Article on The Lancet
Stay updated on all scientific advances with Hemostasis Today.
-
May 23, 2026, 01:51Paula Greter: Access and Innovation in Hemophilia through ERAH2026
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality
-
May 22, 2026, 17:24Jim Hoffman: A New Approach to Balancing Host Defense and Tissue Protection
-
May 22, 2026, 17:22Lucia Rugeri: Advancing Multidisciplinary Care for Heavy Menstrual Bleeding in Women with Bleeding Disorders
-
May 22, 2026, 17:20Nour Al-Mozain: Optimizing PBSC Collection Through Real-Time CD34+ Monitoring
-
May 22, 2026, 16:30Buse Bor: New Publication on Therapeutic Interventions for Women with Obstetric APS
-
May 22, 2026, 16:29Danny Hsu: The Reversal Dilemma – Rethinking our approach to DOAC-associated ICH
-
May 22, 2026, 16:28Bartosz Hudzik: High Bleeding Risk Does Not Always Mean Bleeding-Risk Predominance